Página 98 – SEIOMM, Sociedad Española de Investigación Ósea

TBS and BMD at the end of AI-therapy: A prospective study of the B-ABLE cohort

AI therapy induces significant decreases in TBS, comparable to BMD loss. BP-treated patients maintained TBS values, whereas BMD increased. AI treatment leads to deterioration of bone microarchitecture, which seems to be attenuated by BP therapy.

Objectively Verified Parental Hip Fracture Is an Independent Risk Factor for Fracture: a Linkage Analysis of 478,792 Parents and 261,705 Offspring

J Bone Miner Res. 2016 Sep;31(9):1753-9. doi: 10.1002/jbmr.2849. Epub 2016 Apr 30. Parental Hip Fracture (HF) increased the risk for offspring Major Osteoporotic Fracture (MOF) and HF but not when parental HF occurred after age … Leer más

Triglyceride Levels and Fracture Risk in Midlife Women: Study of Women’s Health Across the Nation (SWAN)

J Clin Endocrinol Metab. 2016 Sep;101(9):3297-305. doi: 10.1210/jc.2016-1366. Epub 2016 Jun 13. CONCLUSIONS: Midlife women with high fasting plasma TG had an increased risk of incident nontraumatic fracture. Secondary Abstract: Midlife women with fasting plasma … Leer más

Links Between the Microbiome and Bone

J Bone Miner Res. 2016 Sep;31(9):1638-46. doi: 10.1002/jbmr.2887. Epub 2016 Jul 26. Despite these challenges, an understanding of the mechanisms by which the gut microbiome affects bone has the potential to provide insights into the … Leer más

Potential Usefulness of BMD and Bone Turnover Monitoring of Zoledronic Acid Therapy Among Women With Osteoporosis: Secondary Analysis of Randomized Controlled Trial Data

J Bone Miner Res. 2016 Sep;31(9):1767-73. doi: 10.1002/jbmr.2847. Epub 2016 Apr 25. In conclusion, serum PINP is potentially useful in monitoring response to zoledronic acid. Further research is needed to evaluate the effects of monitoring … Leer más

250b62e6de26c8f8068c793bc5312cf9038207fd

Programa 6ª Convocatoria PostASBMR 2016 y Curso SEIOMM-ECTS MRO

Programa

9:00-9:10 Apertura. Josep Blanch, Presidente SEIOMM.

9:10-11:30 Mesa de Discusión I Moderador: Federico Hawkins

9:10-9:45 Lo más importante del ASBMR 2016 Annual Meeting. Abstracts: novedades acerca de bisfosfonatos, fallo terapéutico. Odanacatib. Jesús González Macías

9:45-10:05 BMPs in Development and Disease. Abstracts: Sistema OPG, RANK, RANKL. Ramón Pérez Cano

10:05-10:30 Personalized Medicine. Can We Close the Treatment Gap for Osteoporosis? Abstracts: Anticuerpos antiesclerostina y hueso. Manuel Muñoz Torres

10:30-10:50 Gut Microbiome and Bone Homeostasis. Abstracts: Teriparatida y Abaloparatida. Esteban Jódar

10:50-11:10 The Importance of Cortical Bone through the Life Span. Abstracts: Biomecánica y técnicas novedosas de medición de la calidad Adolfo Díez Pérez

Convocatoria BECAS FEIOMM INVESTIGACIÓN 2016

La Fundación Española de Investigación Ósea y del Metabolismo Mineral (FEIOMM), convoca 6 BECAS de 6.000€ cada una para promocionar la investigación básica, clínica y traslacional en el campo del metabolismo mineral y óseo. Consulte … Leer más

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial

JAMA. 2016 Aug 16;316(7):722-33. doi: 10.1001/jama.2016.11136. Among postmenopausal women with osteoporosis, the use of subcutaneous abaloparatide, compared with placebo, reduced the risk of new vertebral and nonvertebral fractures over 18 months. Further research is needed … Leer más

Effects of antidepressants on postmenopausal bone loss – A 5-year longitudinal study from the OSTPRE cohort

Bone. 2016 Aug;89:25-31. doi: 10.1016/j.bone.2016.05.003. Epub 2016 May 11. In conclusion, the use of SSRIs seems to accelerate postmenopausal bone loss in a dose-response manner. Associations between TCA and other antidepressant use and bone loss … Leer más

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates

J Clin Endocrinol Metab. 2016 Aug;101(8):3163-70. doi: 10.1210/jc.2016-1801. Epub 2016 Jun 6 In postmenopausal women with osteoporosis previously treated with oral bisphosphonates, denosumab was associated with greater BMD increases at all measured skeletal sites and … Leer más

Blog